Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G R Oxnard

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Clinical Pharmacology and Therapeutics|February 14, 2015
ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancerD E Gerber, G R Oxnard, R Govindan
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2021
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNAM C Liu, G R Oxnard, E A Klein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2019
Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancerG M Blumenthal, Y Gong, K Kehl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 12, 2018
Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancerN Guibert, Y Hu, N Feeney, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Relationship of tumor fraction in circulating tumor DNA with prognosis in patients with advanced urothelial cancerB Miron, G Li, J C F Quintanilha, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 8, 2022
Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes studyZ R Reichert, T M Morgan, G Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2018
Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertionsZ Piotrowska, D B Costa, G R Oxnard, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Toward optimizing patient selection for EGFR antibody therapies in metastatic colorectal cancer: outcomes and resistance features in real-world dataM J Emmett, J C F Quintanilha, R P Graf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 7, 2020
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancerG R Oxnard, J C-H Yang, H Yu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2019
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome ConsortiumB T Li, F Janku, B Jung, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Clinical Pharmacology and Therapeutics|February 14, 2015
ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancerD E Gerber, G R Oxnard, R Govindan
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2021
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNAM C Liu, G R Oxnard, E A Klein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2019
Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancerG M Blumenthal, Y Gong, K Kehl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 12, 2018
Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancerN Guibert, Y Hu, N Feeney, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Relationship of tumor fraction in circulating tumor DNA with prognosis in patients with advanced urothelial cancerB Miron, G Li, J C F Quintanilha, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 8, 2022
Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes studyZ R Reichert, T M Morgan, G Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 24, 2018
Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertionsZ Piotrowska, D B Costa, G R Oxnard, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Toward optimizing patient selection for EGFR antibody therapies in metastatic colorectal cancer: outcomes and resistance features in real-world dataM J Emmett, J C F Quintanilha, R P Graf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 7, 2020
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancerG R Oxnard, J C-H Yang, H Yu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2019
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome ConsortiumB T Li, F Janku, B Jung, et al.
Pageof 1